CLEARSIDE BIOMEDICAL INC (CLSD)
US1850631045 - Common Stock
Overall CLSD gets a fundamental rating of 3 out of 10. We evaluated CLSD against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CLSD have multiple concerns. CLSD is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
CLSD had negative earnings in the past year.
CLSD had a negative operating cash flow in the past year.
CLSD had negative earnings in 4 of the past 5 years.
CLSD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -109.31%, CLSD is doing worse than 78.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.31% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-52.95%
ROA(5y)-73.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 102.18%, CLSD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
CLSD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 102.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLSD does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLSD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLSD has been increased compared to 5 years ago.
There is no outstanding debt for CLSD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CLSD has an Altman-Z score of -17.77. This is a bad value and indicates that CLSD is not financially healthy and even has some risk of bankruptcy.
CLSD has a worse Altman-Z score (-17.77) than 83.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.77 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
CLSD has a Current Ratio of 4.49. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.49, CLSD is doing good in the industry, outperforming 63.87% of the companies in the same industry.
CLSD has a Quick Ratio of 4.49. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
CLSD's Quick ratio of 4.49 is fine compared to the rest of the industry. CLSD outperforms 65.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.49 | ||
| Quick Ratio | 4.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 29.51% over the past year.
The Revenue has grown by 248.55% in the past year. This is a very strong growth!
The Revenue has been growing by 207.34% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)248.55%
Revenue growth 3Y1.4%
Revenue growth 5Y207.34%
Sales Q2Q%20.84%
3.2 Future
CLSD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.16% yearly.
CLSD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.73% yearly.
EPS Next Y8.26%
EPS Next 2Y5.28%
EPS Next 3Y1.74%
EPS Next 5Y15.16%
Revenue Next Year-77.77%
Revenue Next 2Y-25.79%
Revenue Next 3Y20.95%
Revenue Next 5Y63.73%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLSD. In the last year negative earnings were reported.
Also next year CLSD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.28%
EPS Next 3Y1.74%
5. Dividend
5.1 Amount
CLSD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CLEARSIDE BIOMEDICAL INC
NASDAQ:CLSD (12/20/2024, 8:02:44 PM)
After market: 0.91 +0.04 (+4.32%)0.8723
-0.06 (-6.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners26.35%
Inst Owner Change-26.66%
Ins Owners1.46%
Ins Owner Change0.73%
Market Cap66.16M
Analysts84.62
Price Target6.12 (601.59%)
Short Float %1.9%
Short Ratio1.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.25%
Min EPS beat(2)21.12%
Max EPS beat(2)27.38%
EPS beat(4)3
Avg EPS beat(4)13%
Min EPS beat(4)-6.87%
Max EPS beat(4)27.38%
EPS beat(8)4
Avg EPS beat(8)2.97%
EPS beat(12)6
Avg EPS beat(12)-17.59%
EPS beat(16)8
Avg EPS beat(16)-14.87%
Revenue beat(2)1
Avg Revenue beat(2)348.98%
Min Revenue beat(2)-30.34%
Max Revenue beat(2)728.3%
Revenue beat(4)2
Avg Revenue beat(4)169.2%
Min Revenue beat(4)-61.45%
Max Revenue beat(4)728.3%
Revenue beat(8)5
Avg Revenue beat(8)243.24%
Revenue beat(12)6
Avg Revenue beat(12)150.25%
Revenue beat(16)8
Avg Revenue beat(16)103.39%
PT rev (1m)2.44%
PT rev (3m)7.69%
EPS NQ rev (1m)20.99%
EPS NQ rev (3m)20.99%
EPS NY rev (1m)3.56%
EPS NY rev (3m)3.84%
Revenue NQ rev (1m)73.06%
Revenue NQ rev (3m)73.06%
Revenue NY rev (1m)153.64%
Revenue NY rev (3m)153.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.1
BVpS-0.46
TBVpS-0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.31% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 102.18% | ||
| FCFM | N/A |
ROA(3y)-52.95%
ROA(5y)-73.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 396.34% | ||
| Cap/Sales | 8.44% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.49 | ||
| Quick Ratio | 4.49 | ||
| Altman-Z | -17.77 |
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)939.64%
Cap/Depr(5y)573.3%
Cap/Sales(3y)13.47%
Cap/Sales(5y)8.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y8.26%
EPS Next 2Y5.28%
EPS Next 3Y1.74%
EPS Next 5Y15.16%
Revenue 1Y (TTM)248.55%
Revenue growth 3Y1.4%
Revenue growth 5Y207.34%
Sales Q2Q%20.84%
Revenue Next Year-77.77%
Revenue Next 2Y-25.79%
Revenue Next 3Y20.95%
Revenue Next 5Y63.73%
EBIT growth 1Y17.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.68%
EBIT Next 3Y1.69%
EBIT Next 5YN/A
FCF growth 1Y-585.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-601.82%
OCF growth 3YN/A
OCF growth 5YN/A